Premium
The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG
Author(s) -
LunaCoronell Johana A.,
Vierlinger Klemens,
Gamperl Magdalena,
Hofbauer Johann,
Berger Ingrid,
Weinhäusel Andreas
Publication year - 2016
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201500378
Subject(s) - antibody microarray , antigen , biology , microarray , protein microarray , prostate cancer , proteomics , gene expression profiling , in silico , microarray analysis techniques , dna microarray , immune system , cancer research , antibody , immunology , cancer , gene expression , gene , genetics
The study of the immunome of prostate cancer (PCa) and characterization of autoantibody signature from differentially reactive antigens can uncover disease stage proteins, reveal enriched networks and even expose aberrant cellular mechanisms during the disease process. By conducting plasma IgG profiling on protein microarrays presenting 5449 unique human proteins expressed in 15 417 E. coli human cDNA expression clones, we elucidated 471 (21 higher reactive in PCa) differentially reactive antigens in 50 PCa versus 49 patients with benign prostate hyperplasia (BPH) at initial diagnosis. Functional analyzes show that the immune‐profile of PCa compared to BPH control samples is significantly enriched in features targeting Cellular assembly , Cell death and pathways involved in Cell cycle, translation, and assembly of proteins as EIF2 signaling, PCa related genes as AXIN1 and TP53, and ribosomal proteins (e.g. RPS10). An overlap of 61 (out of 471) DIRAGs with the published 1545 antigens from the SEREX database has been found, however those were higher reactive in BPH. Clinical relevance is shown when antibody‐reactivities against eight proteins were significantly ( p < 0.001) correlated with Gleason‐score. Herewith we provide a biological and pathophysiological characterization of the immunological layer of cancerous (PCa) versus benign (BPH) disease, derived from antibody profiling on protein microarrays.